Lambda Biologics

Startseite
Deutschland
Leipzig
Lambda Biologics

Lambda Biologics is a hub for bio-health knowledge and research, offering an advanced testing platform.

Explore animal-free solutions and experience fast and accurate results with the enhanced services of MyLab.

23/04/2026

Thank you for joining us at AACR Annual Meeting 2026 - it was a pleasure connecting with so many innovators shaping the future of cancer research.

At the meeting this year, we were proud to present the Lambda Award, recognizing excellence in biological research across:
• Technology Excellence Award
• Lambda AFI Award (advancing animal-alternative methods)
• Bio Award (biological imaging & storytelling)

We continue to welcome researchers, labs, partners, and service providers advancing NAMs to connect with us. Let’s collaborate to accelerate more predictive, human-relevant science.

20/04/2026

🚀 Day 1 at AACR 2026 – The Battle Begins!
Meet our Stormtrooper at Booth #1603 👀

At Lambda Biologics, we’re bringing the galaxy to cancer research with our theme: “𝐓𝐌𝐄 𝐈𝐧𝐭𝐞𝐫𝐩𝐥𝐚𝐲 𝐰𝐢𝐭𝐡 𝐎𝐫𝐠𝐚𝐧𝐨𝐢𝐝𝐬.”
Step into our “Galactic Empire” and discover how our advanced organoid platforms are engineered to replicate the complexity of the tumor microenvironment (TME) — where immune cells and tumors constantly interact, compete, and evolve.

But we’re not just showcasing science — we’re making it interactive:
🧬 Build your own TME with our 3D stamping activity
🎯 “Kill the tumor” with our AR experience
🎁 Win exclusive gifts
💬 Talk to our team about your projects - and unlock special AACR discounts
[Link in Bio]

Whether you're exploring immuno-oncology, drug screening, or TME modeling, this is your chance to see how organoids can bring your research closer to real human biology.

📍 Booth #1603
👋 Come say hi — and join the fight against cancer.
hashtag hashtag hashtag hashtag hashtag hashtag

17/04/2026

[New Platform Updates]

A new lens on MDSC-driven tumor immunosuppression

Myeloid-derived suppressor cells (MDSCs) are key drivers of immunosuppression and therapy resistance in cancer, actively shaping the tumor microenvironment (TME) by suppressing T-cell function and promoting tumor progression. Their accumulation and trafficking into tumors are tightly regulated by tumor- and stroma-derived signals, particularly from cancer-associated fibroblasts.

We developed a co-culture platform based on a Transwell system that integrates MDSC-like cells with to enable quantitative measurement of MDSC trafficking and infiltration. In parallel, the platform incorporates functional co-culture assays to assess MDSC-mediated immunosuppression. Together, this system supports evaluation of MDSC-targeted anticancer agents through their effects on both immune suppression and migration/infiltration in a multicellular context.

Read more: https://bit.ly/3OwuuvT
Poster Presentation at AACR 2026 - Come Find Us!

📍 Session LBPO.IM02 – Late-Breaking Research: Immunology 2
📌 LB153/18 – A quantitative MDSC infiltration assay in a tumor organoid-stromal microenvironment for immuno-oncology candidate evaluation
⏰ April 20, 2026 | 9:00 AM – 12:00 PM | Section 53
✅ Book a meeting with us: [Link in Bio]

14/04/2026

Antibody-Drug Conjugates (ADCs) hold incredible promise in oncology, but traditional preclinical models often fall short. 2D cell lines lack the 3D architecture and tumor microenvironment (TME), while animal models struggle with species-specific differences in antigen expression and drug metabolism. The result? Poor translation to human responses, unexpected toxicities, and delayed pipelines.

That’s why we’re excited to showcase Lambda Biologics’ 𝐇𝐮𝐦𝐚𝐧 𝐎𝐫𝐠𝐚𝐧𝐨𝐢𝐝-𝐁𝐚𝐬𝐞𝐝 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐀𝐃𝐂 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐚𝐧𝐝 𝐓𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐨𝐧.

✅ Built on patient-derived 3D organoids that preserve tumor genetics and phenotypes
✅ Recapitulates complex tumor microenvironment (TME) interactions
✅ Enables simultaneous assessment of anti-tumor efficacy and off-target toxicity
✅ Delivers more clinically relevant insights than conventional 2D or animal models

Contact us to discuss your ADC development project!
Read more: https://bit.ly/4vyUzeC

10/04/2026

Tumor heterogeneity remains a defining feature of Non-small cell lung cancer (NSCLC) and a major barrier to therapeutic efficacy. Genetically and phenotypically diverse subclones - shaped by oncogenic alterations, clonal evolution, and dynamic cellular states - can coexist within the same tumor, driving differential drug response and resistance.

Conventional 2D cell lines inadequately capture this complexity, often failing to preserve intra-tumoral heterogeneity and clinically relevant signaling contexts.

At , our NSCLC organoid platform is designed to retain key features of patient tumors, including:

✅ Intra-tumoral heterogeneity across subclonal populations
✅ Patient-specific molecular and phenotypic profiles
✅ Genetic alterations and protein expression patterns

The platform is further supported by mutation profiling and drug response datasets across multiple NSCLC organoid lines, enabling more informed evaluation of targeted therapies and drug sensitivity.

📌 By maintaining critical aspects of tumor biology, these models provide a more physiologically relevant system for preclinical research. Learn more: https://afs.lambda-bio.com/afs/lung-cancer-organoid/

07/04/2026

Poster Presentation at AACR 2026 - Come Find Us!

📍 Session LBPO.IM02 – Late-Breaking Research: Immunology 2
📌 LB153/18 – A quantitative MDSC infiltration assay in a tumor organoid-stromal microenvironment for immuno-oncology candidate evaluation
⏰ April 20, 2026 | 9:00 AM – 12:00 PM | Section 53
✅ Book a meeting with us: https://calendar.app.google/Nk7hGn14LvV9nQBh8

MDSCs are among the most powerful drivers of immunosuppression in cancer - shutting down T-cell responses, remodeling the tumor microenvironment, and fueling therapy resistance. Studying them in a meaningful context requires more than simple monocultures.

At , we developed a Transwell-based co-culture platform integrating MDSC-like cells, tumor organoids, and stromal components. The system delivers two complementary readouts in one model: quantitative MDSC infiltration and functional immunosuppression assessment - making it a more physiologically relevant tool for evaluating MDSC-targeted agents, ADCs, and next-generation immuno-oncology candidates.

Come see the data at our poster, and visit us at Booth 1603 (April 17–22) to explore how our oncology organoid platform could support your pipeline.

03/04/2026

Antibody-drug conjugates (ADCs) development demands models that reflect tumor complexity - not just cell lines.

Our ODISEI ONC platform is built on patient-derived organoids that preserve native tumor heterogeneity, integrated with stromal and immune components to closely mirror the in vivo tumor microenvironment.

From evaluating payload-linker efficacy and profiling antigen expression across tumor subtypes to first-in-platform efficacy screens, Lambda Biologics brings the scientific depth and infrastructure your ADC program needs - at every stage of development.

📌 Ready to accelerate your ADC pipeline? Let's talk.
https://afs.lambda-bio.com/organoid-service/oncology/

01/04/2026

Can a cholesterol-lowering drug fight cancer?

A study published in Cell Death & Disease - a Nature Portfolio journal - revealed that Lomitapide, an FDA-approved drug for familial hypercholesterolemia, exerts potent anticancer activity by inhibiting mTORC1 and triggering autophagic cell death across multiple cancer types.

Crucially, its efficacy was validated using patient-derived CRC organoids, where Lomitapide outperformed 5-FU, a standard first-line chemotherapy.

📌 Read the full study: https://www.nature.com/articles/s41419-022-05039-6
📌 Interested in Colorectal Cancer Organoids? Contact Lambda Biologics to learn more: https://afs.lambda-bio.com/afs/colorectal-cancer-organoid/

25/03/2026

Did you know tumors don’t act alone?
Cancer cells constantly communicate with their surroundings - immune cells, fibroblasts, and the extracellular matrix - forming what scientists call the tumor microenvironment (TME).

This dynamic ecosystem controls:
✅ Immune evasion
✅ Drug response
✅ Tumor progression

But here’s the challenge: Most traditional 2D monocultures isolate tumor cells, removing the very signals that define real tumor behavior. If we study cancer without its environment, we miss the full story.

To address this, Lambda Biologics provides an integrated TME co-culture system designed to better model tumor complexity and evaluate the response of modern oncology therapeutics - including Antibody-Drug Conjugates (ADCs), cell therapies, immunotherapies, and targeted small molecules.

Heading to AACR Annual Meeting 2026?
Visit us at Booth 1603 or book a meeting to discuss how your current models can better capture tumor–microenvironment interactions.

📌 April 17–22 San Diego Convention Center
📍 Booth 1603 | TME Interplay with Organoids
🔗 Book a meeting with us: https://calendar.app.google/Nk7hGn14LvV9nQBh8

23/03/2026

Congratulations to ORGANOIDSCIENCES on receiving IND approval from Korea’s MFDS for ATORM-C - an intestinal organoid-based regenerative therapy entering Phase 1 clinical trials for Crohn’s disease.

This milestone highlights the growing role of organoids in regenerative medicine - a field that Lambda Biologics is proud to help advance in partnership with ORGANOIDSCIENCES. In 2024, this platform secured a public funding from the Free State of Saxony, supported by the European Union, to accelerate the development of therapies within the Advanced Therapy Medicinal Products (ATMP) framework.

Through this collaboration, we are working to scale human-relevant organoid technologies and bring the next generation of regenerative medicine closer to patients.

A new therapeutic paradigm is emerging - and organoids are at its core.

📌 Read more: https://www.asiae.co.kr/en/article/bio-health/2026031615243829690

21/03/2026

On Brain Awareness Week, Lambda Biologics underscores the growing importance of advanced human-relevant in vitro systems in neuroscience research. 🧠

At Lambda Biologics, our specialized brain organoid research team develops physiologically relevant cerebral organoid models that recapitulate key features of human brain development and pathology. We collaborate with academic and industry partners to study neurodevelopmental and neurodegenerative disorders, including Alzheimer’s disease, autism spectrum disorder, microcephaly, and epilepsy.

These platforms enable mechanistic investigations, disease modeling, drug discovery, neurotoxicity assessment, and functional analysis of neuronal network activity in a controlled human context - helping bridge the gap between conventional models and clinical translation.

We welcome collaborative research opportunities to advance translational neuroscience and therapeutic innovation. Learn more: https://afs.lambda-bio.com/afs/cerebral-organoid/

16/03/2026

Visit Lambda Biologics Booth at AACR 2026!
📌 April 17–22 | San Diego Convention Center
📍 Booth 1603 | TME Interplay with Organoid

Learn more: https://afs.lambda-bio.com/blog/join-us-at-the-american-association-for-cancer-research-2026/

At AACR 2026, Lambda Biologics will demonstrate real-time immune–tumor interactions using our oncology-focused organoid platforms - built to capture the complexity that drives immunotherapy response and resistance.

Our integrated tumor organoid–TME platforms let you:
✅ Reconstruct patient-relevant tumor microenvironments in vitro
✅ Enable real-time observation of tumor growth and immune–tumor interactions
✅ Model ECM and stromal influences on tumor behavior
✅ Support mechanistic studies of cancer development
✅ Evaluate drug response and immune modulation in a physiologically relevant setting

🎁 AACR Exclusive Offer: Get 26% off Downstream Analysis for your oncology project.
👉 Book a meeting with us: https://calendar.app.google/Nk7hGn14LvV9nQBh8

Adresse

Deutscher Platz. 5c
Leipzig
04103

Webseite

http://afs.lambda-bio.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Lambda Biologics erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.